Jim Cramer on Immunome: “If You Want to Speculate on It, Fine”

“This company’s losing truthful overmuch money, I know, but it’s Dr. Siegall… So therefore, if you privation to speculate connected it, fine. But we bash not deliberation that you’re investing.”

Pixabay/Public Domain

Immunome, Inc. (NASDAQ:IMNM) is simply a clinical-stage biotech institution that focuses connected processing targeted crab treatments, with a starring cause campaigner successful late-stage investigating and different successful aboriginal objective trials. The company’s pipeline besides includes earlier-stage therapies aimed astatine treating coagulated tumors with much precise approaches. On December 15, 2025, it announced that the Phase 3 RINGSIDE proceedings of varegacestat showed beardown results successful patients with progressing desmoid tumors.

The cause showed a simplification of hazard of illness progression oregon decease by 84% versus placebo. Additionally, it delivered a 56% effect complaint compared with 9% for placebo, and reduced tumor measurement by 83%, and mostly lone showed mild to mean broadside effects. Immunome, Inc. (NASDAQ:IMNM) plans to taxable a New Drug Application to the U.S. Food and Drug Administration successful Q2 2026. Sarcoma aesculapian oncologist and cause improvement specializer and RINGSIDE superior investigator, Mrinal M. Gounder, M.D. said:

“The progression-free endurance benefit, precocious effect complaint and simplification successful tumor measurement with varegacestat successful the RINGSIDE proceedings are striking. These findings elevate the relation of GSIs and corroborate varegacestat could go modular of attraction successful the attraction of desmoid tumors.”

While we admit the imaginable of IMNM arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the champion short-term AI stock.

READ NEXT: 30 Stocks That Should Double successful 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This nonfiction is primitively published astatine Insider Monkey.